Characterization of mesenchymal stem or stromal cells: tissue sources, heterogeneity, and function

Schäfer, Richard

doi:10.1111/trf.13561

Cited by 5 publications

(4 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The past decade has shown that, despite encouraging clinical data, major challenges prevail before MSC therapies can be sustainably implemented in the clinical routine. To date, the poorly understood heterogeneity of MSCs means that major issues are yet to be addressed; for example, between individuals and within respective MSC preparations, variable manufacture technologies, and minimally defined media supplements (such as fetal calf serum or human platelet lysate) [29, 30]. Consequently, it is difficult to compare MSC therapeutics because they lack standardized quality and there are only few measures available – some of debatable relevance – to assess their potency.…”

Section: Challenges and Novel Approachesmentioning

confidence: 99%

Advanced cell therapeutics are changing the clinical landscape: will mesenchymal stromal cells be a part of it?

Schäfer

2019

BMC Med

Self Cite

View full text Add to dashboard Cite

During the past 15 years there have been dramatic changes in the medical landscape, particularly in oncology and regenerative medicine. Cell therapies have played a substantial part in this progress. Cellular immunotherapies can use immune cells, such as T cells or natural killer cells that, after functional modification ex vivo, exert powerful anti-cancer effects when given to the patient. Innovative technologies, such as re-programming terminally differentiated cells into pluripotent stem cells or into other cell types and applying specific enzymes to more precisely edit the human genome, are paving the way towards more potent cell and gene therapies. Mesenchymal stromal cells are promising cellular immunotherapeutics, which also have potential for use in tissue engineering strategies and other regenerative medicine applications. However, substantial gaps in our knowledge of their biology and therapeutic efficacy present major challenges to their sustainable implementation in the clinical routine. In this article, progress in the field of cell therapeutics during the past 15 years will be briefly discussed, with a focus on mesenchymal stromal cells, highlighting the impact of this field on patient care.

show abstract

Section: Challenges and Novel Approachesmentioning

confidence: 99%

Advanced cell therapeutics are changing the clinical landscape: will mesenchymal stromal cells be a part of it?

Schäfer

2019

BMC Med

Self Cite

View full text Add to dashboard Cite

show abstract

“…MScs, also known as mesenchymal stromal cells, are multipotent stromal cells with the ability to differentiate into osteoblasts, adipocytes, chondrocytes and other types of cells under different conditions (12). despite extensive research efforts, the multi-differentiation potential of MScs has only been demonstrated in vitro, and there are few studies describing their characteristics in vivo (13,14). MScs can accelerate wound healing by regulating inflammation (15).…”

Section: Introductionmentioning

confidence: 99%

Research advances in the role of gastric cancer‑derived mesenchymal stem cells in tumor progression (Review)

Shen

Zhu

2020

Int J Mol Med

View full text Add to dashboard Cite

Gastric cancer (Gc) is one of the most common malignancies and the second leading cause of cancer-associated death in the world. The carcinogenesis and development of Gc involves complicated steps and various factors, in which the tumor microenvironment serves a vital role. Mesenchymal stem cells (MScs), also known as mesenchymal stromal cells, are multipotent stromal cells, and have gained increasing attention due to their wound-healing ability, as well as their tumor-promoting potential. MScs are essential components of the tumor microenvironment and serve important roles in tumor initiation, progression and metastasis. The present review focuses on Gc and discusses recent advances in understanding the effect of Gc-derived MSc-like cells (Gc-MScs) on tumor progression, chemoresistance and immune escape. Additionally, the mechanism underlying the tumor tropism of bone marrow-derived MScs and the malignant transition of these cells to Gc-MScs are addressed. The potential of Gc-MScs in the treatment of Gc, such as for predicting prognosis and as therapeutic targets, is also discussed in association with their critical role in tumor progression. The information on the characteristics and functions of Gc-MScs provided in the present review may promote the development of novel therapeutic strategies against Gc. Contents 1. Introduction 2. Biological characteristics of Gc-MScs 3. Formation of Gc-MScs 4. Effects of Gc-MScs on tumor progression and the tumor microenvironment 5. Therapeutic opportunities for Gc-MScs 6. conclusions

show abstract

“…Therefore, therapeutic application of MSCs should be reconsidered in terms of the tissue source of these cells, the methods of isolation and the cell culture conditions that markedly modulate their biological properties and behavior. For example, CB-, BM-, Wharton's jelly-, placenta-, amniotic fluid/ membrane-and AT-derived MSCs differ with respect to their vasculogenic regulatory/stimulating capacity, adipogenic, bone or cartilage differentiation potential and other immunomodulatory functions such as the inhibition of T cell mitogenesis [da Silva Meirelles et al, 2006;Karagianni et al, 2013;Ketterl et al, 2015;Marquez-Curtis et al, 2015;Schäfer and Bieback, 2016]. In addition, the culture conditions of MSCs and preservation modes for their future use in therapeutic strategies should be standardized in order to determine the activities required, including those supporting or modulating/inhibiting vasculogenesis [Kang et al, 2011;Bieback, 2013;Kinzebach and Bieback, 2013].…”

Section: Ways To Improve or Modify The Biologic/vasculogenic Activitimentioning

confidence: 99%

Vasculogenesis and Its Cellular Therapeutic Applications

Ratajska¹,

Jankowska‐Steifer

Czarnowska

et al. 2016

Cells Tissues Organs

View full text Add to dashboard Cite

Vasculogenesis was originally defined by Risau in 1997 [Nature 386: 671-674] as the de novo formation of vessels from endothelial progenitor cells (EPCs), so-called angioblasts. Initially, this process was believed to be related only to embryonic life; however, further studies reported vasculogenesis to occur also in adult tissues. This overview presents the current knowledge about the origin, differentiation and significance of EPCs that have been observed in various diseases, tumors, and reparative processes. We also summarize the knowledge of how to activate these cells for therapeutic purposes and the outcomes of the therapies.

show abstract

Characterization of mesenchymal stem or stromal cells: tissue sources, heterogeneity, and function

Cited by 5 publications

References 27 publications

Advanced cell therapeutics are changing the clinical landscape: will mesenchymal stromal cells be a part of it?

Advanced cell therapeutics are changing the clinical landscape: will mesenchymal stromal cells be a part of it?

Research advances in the role of gastric cancer‑derived mesenchymal stem cells in tumor progression (Review)

Vasculogenesis and Its Cellular Therapeutic Applications

Contact Info

Product

Resources

About